Remove spurious part of URL

README.md

@@ -297,7 +297,7 @@ Note that the WHO will generally be unable to make statements that their more pr
 * [The COVID-19 vaccine development landscape](https://www.nature.com/articles/d41573-020-00073-5), published on Nature on April 9, presenting charts with breakdowns of vaccine types under study and their profit models
 * [A COVID-19 Vaccine: Big Strides Come with Big Challenges](https://www.mdpi.com/2076-393X/9/1/39/htm) discusses the different phases of vaccine development and the various platforms in use for candidate COVID-19 vaccines, including their progress as to January 2021, with the major characteristics of vaccines in advanced phases summarized in Table 1
 * [The Vaccine Tightrope](https://blogs.sciencemag.org/pipeline/archives/2020/10/21/the-vaccine-tightrope) by Derek Lowe analyzes the problem of vaccines being deployed before trials for other vaccines are over, as well as of providing placebo arms with the actual vaccine before the full trial length of two years is completed, with ethical and practical repercussions on participants
-* [mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants](https://www.nature.com/articles/s41586-021-03324-6#article-info) reports on immune response of recipients of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines and notes that activity of their serum against SARS-CoV-2 variants encoding E484K or N501Y or the K417N:E484K:N501Y combination was reduced by a small but significant margin
+* [mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants](https://www.nature.com/articles/s41586-021-03324-6) reports on immune response of recipients of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines and notes that activity of their serum against SARS-CoV-2 variants encoding E484K or N501Y or the K417N:E484K:N501Y combination was reduced by a small but significant margin
 * [Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3789264) shows that the Pfizer/BioNTech (BNT162b2) vaccine was associated with a vaccine effect of 85% against hospitalization at 28-34 days post-vaccination, while the effect of the Oxford/Astrazeneca (ChAdOx1) vaccine was 94%, although the age cohorts in the two vaccines were different, and the efficacy against hospitalization was similar for the two vaccines, at 81%, when looking at people over 80
 * [FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system](https://www.medrxiv.org/content/10.1101/2021.02.15.21251623v2) is a preprint that analyzes more than 60000 individuals at Mayo Clinic, dividing them into a vaccinated cohort (with Pfizer/BioNTech or Moderna) and an unvaccinated one, and retrospectively concluding there was 88.7% efficacy in preventing infection, i.e. a positive RT-PCR test at all, and hence likely also contagiousness, as opposed to just symptomatic cases, which was the benchmark of most of the vaccine trials